long intergenic non-protein coding RNA 1823Genealiases: []
Q-omics provides the consensus-scored LINC01823 profile across patient tissues and cancer cell-line models. LINC01823 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01823 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, LINC01823 RNA expression shows 6,806 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, HNSC, and STAD as cancer lineages where LINC01823 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01823 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01823 survival associations across molecular data types. LINC01823 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01823 RNA expression–survival associations across cancer types. High LINC01823 expression shows unfavorable associations in KIRP, PAAD, DLBC, LUAD, LGG and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01823 RNA expression.
This table summarizes LINC01823 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01823. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01823 shows lower tumor expression in CHOL and higher tumor expression in HNSC, LUSC, LUAD, LIHC and THCA. The HNSC box plot shows higher LINC01823 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .004).
This table shows molecular features associated with LINC01823 in patient tissues and cancer cell lines. In patient samples, LINC01823 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
